The forecasted production of medicaments containing penicillins, streptomycins, or derivatives in Germany from 2024 to 2028 shows a significant declining trend. With values starting at €34.866 million in 2024 and decreasing to €6.9554 million by 2028, the data illustrates a consistent downward trajectory.

Year-on-year percentage variations depict a steep decline, with substantial reductions forecasted for each subsequent year. The compound annual growth rate (CAGR) from 2024 to 2028 is expected to be notably negative, underlining the consistent decrease in production value.

Future trends to watch for:

Changes in global demand and supply chain factors that might impact production costs and volumes.
Potential shifts in regulatory policies affecting the pharmaceutical industry in Germany and the EU.
Technological advances that may disrupt or alter current production processes in the industry.